Delivery is one of the most critical factors. Whether we're dealing with a drug or a natural compound from a supplement, having the right 'ingredient' means nothing if we can't get it to the right place. Our body lives outside the controlled environment of a petri dish.
And now, we see another important step forward in overcoming that challenge...
A team of German and US researchers have developed a new gene-editing delivery system called ENVLPE that uses virus-like particles to transport fully assembled CRISPR-based editors into living cells more safely and efficiently.
Unlike older methods like AAVs or lipid nanoparticles, ENVLPE avoids immune reactions and delivers tools in their complete, protected form. In mouse models, it restored vision from inherited blindness using over 10 times less dose than competing systems.
The technology holds major promise for prostate cancer by enabling precise genetic edits and improving T cell engineering. Future developments aim to target specific tissues—potentially making prostate cancer treatments more effective, accessible, and customizable.
New prostate cancer diagnosis @ 52
Seminal Vesicle Invasion & Senescent tumor cells.
PSA Tests - Yes or No
Yale develops new form of Immunotherapy...
